Core Points - The core announcement is about Sinovac Biotech (688136.SH) planning to transfer 5% of its shares, equivalent to 10.0628 million shares, through a non-public offering to qualified institutional investors [1] Group 1: Share Transfer Details - The controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (referred to as "Keyi Pharmaceutical"), is initiating the share transfer due to its operational development needs [1] - The transfer will be organized by China International Capital Corporation (CICC), with a minimum transfer price set at 70% of the average stock price over the 20 trading days prior to the issuance of the subscription invitation [1] - Previously, Keyi Pharmaceutical completed a transfer of 6.0377 million shares in August, representing 3% of the total share capital, at a price of 36.70 yuan per share [1] Group 2: Institutional Participation - A total of 13 institutional investors, including ICBC Credit Suisse, Caitong Fund, and J.P. Morgan, successfully acquired shares in the previous transfer, which are subject to a six-month lock-up period [1]

Core Viewpoint - The shareholder Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. plans to transfer 10,062,800 shares of Sinovac Biotech, accounting for 5.00% of the company's total share capital, for its own operational development needs [1][2]. Group 1: Share Transfer Details - The transfer is a non-public transfer and will not be conducted through centralized bidding or block trading, meaning it is not a secondary market reduction [2][3]. - The transferee must be an institutional investor with appropriate pricing capability and risk tolerance [2]. - As of September 12, 2025, Koyi Pharmaceutical holds 119,751,430 shares, representing 59.50% of the company [2]. Group 2: Previous Share Transfers - On July 30, 2025, Koyi Pharmaceutical had previously planned to transfer 6,037,717 shares, which accounted for 3.00% of the total share capital, also for funding needs [3]. - The transfer price for the previous transaction was set at 36.70 CNY per share, totaling approximately 221.58 million CNY [3]. - Koyi Pharmaceutical had reduced its holdings by 5,989,200 shares between June 26 and July 9, 2025, at prices ranging from 32.84 to 48.37 CNY per share, amounting to a total of approximately 220.99 million CNY [3][4]. Group 3: Company Financials and Future Plans - Sinovac Biotech was listed on the Shanghai Stock Exchange on December 14, 2020, with an initial public offering (IPO) price of 22.33 CNY per share, raising a total of 1.11 billion CNY [4]. - The actual net fundraising was 995 million CNY, which was 710 million CNY less than the originally planned amount of 1.705 billion CNY [4]. - The company is currently planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [5].

Core Viewpoint - The announcement details a share transfer plan by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to transfer 10,062,800 shares of Kexing Pharmaceutical, representing 5.00% of the total share capital, through a non-public inquiry transfer process [3][7]. Group 1: Share Transfer Details - The total number of shares to be transferred is 10,062,800, which accounts for 5.00% of the company's total share capital [3][7]. - The transfer is organized by China International Capital Corporation (CICC) and is not conducted through public trading methods [3][10]. - The receiving party must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][10]. Group 2: Seller Information - The seller, Shenzhen Keyi Pharmaceutical, is the controlling shareholder of Kexing Pharmaceutical, with a shareholding exceeding 5% [3][4]. - The seller has confirmed that the shares are free from any transfer restrictions and have been released from lock-up [4][5]. Group 3: Pricing Mechanism - The minimum transfer price will not be lower than 70% of the average trading price of the company's shares over the 20 trading days prior to the issuance of the subscription invitation [8]. - The pricing determination will follow a priority system based on subscription price, quantity, and time of submission [9]. Group 4: Company Status - Kexing Pharmaceutical does not have any undisclosed operational risks or potential changes in control related to this share transfer [11]. - There are no other significant undisclosed matters concerning the company [11].

股东询价转让计划书 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"） 的股东为深圳科益医药控股有限公司； 出让方拟转让股份的总数为 10,062,800 股，占公司总股本的比例为 5.00%； 证券代码：688136 证券简称：科兴制药 公告编号：2025-075 科兴生物制药股份有限公司 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 ...

中国国际金融股份有限公司 关于科兴生物制药股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受科兴生物制药股份有限 公司（以下简称"科兴制药"）股东深圳科益医药控股有限公司（以下简称"深圳科 益""出让方"）委托，组织实施本次科兴制药股东向特定机构投资者询价转让（以 下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上 市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询 价转让和配售指引》"）等相关规定，中金公司对参与本次询价出让方的相关资格进 行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求，中金公司已完成出让方相关资格的核查工作，包括核查出让 方提供的营业执照、《承诺及声明函》等， ...

Group 1 - The core point of the article is that Sinovac Biotech (688136.SH) has announced a shareholder inquiry transfer plan, where Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. intends to transfer a total of 10.0628 million shares, representing 5.00% of the company's total share capital [1]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]